Formycon AG (LON: 0W4N)

Market Cap	822.77M
Revenue (ttm)	51.55M
Net Income (ttm)	54.17M
Shares Out	n/a
EPS (ttm)	3.24
PE Ratio	15.19
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60
Average Volume	8,631
Open	55.50
Previous Close	55.40
Day's Range	55.20 - 55.50
52-Week Range	46.50 - 80.20
Beta	0.84
RSI	49.78
Earnings Date	Mar 27, 2025

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara used in ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1999
• Employees: 238
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0W4N

Financial Performance

In 2023, Formycon AG's revenue was 77.70 million, an increase of 82.83% compared to the previous year's 42.50 million. Earnings were 75.80 million, an increase of 110.59%.

Financial numbers in EUR